- Company
- Celltrion tops KRW 1T in 2024 sales
- by Chon, Seung-Hyun Feb 26, 2025 06:29am
- Celltrion's sales and operating profit are reported to be the highest in history due to expanded sales of biosimilars. Its sales exceeded KRW 1 trillion in both North American and European markets. According to the Financial Supervisory Service (FSS), Celltrion's operating profit for last year was KRW 1.2110 trillion, up 89.7% from the previo
- Company
- Samsung Bioepis launches Stelara biosimilar Pyzchiva in US
- by Whang, byung-woo Feb 26, 2025 06:29am
- Samsung Bioepis announced on the 25th that its autoimmune disease treatment Pyzchiva (ustekinumab) has been launched in the US through its marketing partner Sandoz. Stelara’s biosimilar Pyzchiva is Janssen’s treatment for autoimmune diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara’s a
- Policy
- Priority mkt authorization for Trajenta generics ends
- by Lee, Tak-Sun Feb 25, 2025 05:57am
- As the priority marketing authorization for the generic version of Trajenta (linagliptin), a DPP-4 inhibitor used to treat diabetes, launched last year will end on March 8, generics that have been waiting for 10 months will be launched. The list of generics to be launched includes Hanmi Pharmaceutical and Genuone Sciences. According to
- Policy
- Only Rinvoq to undergo drug pricing reduction
- by Lee, Tak-Sun Feb 25, 2025 05:57am
- As the reimbursement of drug switching between biological agents and JAK inhibitors for the treatment of severe atopic dermatitis will be implemented next month, additional claim amounts are reported to be insignificant. Rinvoq ER Tab (AbbVie, upadacitinib) is the only product to see drug pricing reduction due to the expected additional
- Policy
- Generic drugs enter KRW 150 billion Prolia market
- by Lee, Tak-Sun Feb 25, 2025 05:57am
- A competitor to Prolia (Amgen, co-marketed by Chong Kun Dang), which has dominated the market for osteoporosis treatment with its convenience and efficacy, will be released next month. Celltrion will make the launch. Celltrion plans to launch its biosimilar after the expiration of the Prolia product patent on the 17th of next month. Ac
- Company
- Celltrion’s Actemra biosimilar Avtozma receives EU approval
- by Chon, Seung-Hyun Feb 25, 2025 05:56am
- Celltrion announced on the 24th that it has received approval from the European Commission (EC) for the marketing authorization of its ‘Avtozma, a biosimilar of the autoimmune disease treatment 'Actemra (tocilizumab).’ The final approval was granted 2 months after receiving a recommendation for approval from the Committee for Medicinal P
- Company
- Antibody drugs, AI, and platform companies go public
- by Cha, Jihyun Feb 25, 2025 05:56am
- Domestic pharmaceutical, bio, and healthcare companies are floating IPOs one after another. Organoid Sciences is the first to challenge the market with its &160;gap technology. IntoCell plans to submit a securities report as early as next month. Companies in various fields, including biotech companies that develop new drugs, medical artificial
- Company
- Will overcoming CDRC review lead to reimb for 'Besremi'?
- by Eo, Yun-Ho Feb 25, 2025 05:56am
- Whether 'Besremi,' used to treat polycythemia vera, will be added to the National Health Insurance reimbursement list has gained attention. According to the industry sources, PharmaEssentia's Besremi (ropeginterferon alfa-2b) is awaiting to be considered for the Health Insurance Review and Assessment Service (HIRA)'s Drug Reimbursement Ev
- Company
- "Increasing role of Kisqali in breast cancer therapy"
- by Whang, byung-woo Feb 24, 2025 05:51am
- The introduction of CDK 4/6 inhibitors has changed the treatment paradigm for metastatic breast cancer, addressing previously unmet needs. The introduction of a new treatment option has been positively evaluated because the existing endocrine therapy, which is used as first-line treatment for HR+/HER2 advanced and metastatic breast cancer, ac
- Company
- Will Prevnar 20 be included in NIP in 1H 2025?
- by Whang, byung-woo Feb 24, 2025 05:51am
- Pfizer is seeking to release Pfizer’s new pneumococcal vaccine, Prevenar 20, in the first half of this year with its inclusion in the National Immunization Program (NIP) for children. According to industry sources, the Korea Disease Control and Prevention Agency and Pfizer have made progress in discussions on whether Prevnar20 should be
